Hussein H, Zaccardi F, Khunti K, et al. - In adults with type 2 diabetes, researchers conducted this systematic review and network meta-analysis to compare the effectiveness and tolerability of sodium-glucose co-transporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs). Electronic databases were explored from beginning to 24th April 2019 for randomized controlled trials reporting the change in glycated hemoglobin (HbA_1c) at nearly 24 and/or 52 weeks for SGLT-2is and/or GLP-1RAs (classified as short-and long-acting). The sample consisted of 31,384 candidates. Long-acting GLP-1RAs demonstrated superiority in lowering HbA_1c levels, body weight, and waist circumference. SGLT-2is demonstrated decreased blood pressure levels. SGLT-2is exhibited increased chances of genital infection in comparison to long-acting GLP-1RAs, on the other hand, GLP-1RAs displayed increased chances of diarrhea in comparison to SGLT-2is. This analysis provides important information to guide decisions for treatment when treating type 2 diabetes.